Mohn Cancer Research Laboratory
Study using PARP-inhibitors

Targeted therapy

Bergens Tidende shares the story of Aud and Kristel on 5 November; two ladies who have both been treated for breast cancer.

Articel print screen Bergens Tidende
Print screen, Bergens Tidende 5 November 2020

Main content

Chief physician and researcher Hans Petter Eikesdal has been interviewed in Bergens Tidende about the study that Aud Pisani had the opportunity to participate in when she was diagnosed with breast cancer.

The included patients are treated with Parp inhibitors; a drug that disrupts and creates chaos in the cancer cells so that they die.

"-We see that there are more who have the effect of such a treatment. It is much more gentle than traditional chemotherapy" says Eikesdal to the newspaper. Read more about the study here.

The whole article can be read here.